Introduction: Myxofibrosarcoma is a rare and aggressive soft tissue sarcoma with high recurrence and metastasis rates. The prognosis in advanced metastatic disease is poor, with median survival time ranging from 12 to 24 months despite multimodal therapy. Integrative oncology approaches, such as high-dose vitamin C and Viscum album, are increasingly explored as adjuncts in both curative and palliative cancer care. Objective: To describe the clinical course and outcomes of a patient with advanced unresectable myxofibrosarcoma treated with conventional and complementary oncology strategies. Case Presentation: We present the case of a 59-year-old male with high-grade myxofibrosarcoma of the right buttock and spinal metastases. Standard palliative treatments (systemic chemo and radiotherapy, followed by targeted and immunotherapy) were combined with high-dose intravenous vitamin C and Viscum album extracts given intravenously, subcutaneously, and intratumorally. Results: Despite the progression of the disease and COVID-19 comorbidity, the patient survived for 48 months, exceeding conventional survival estimates. Conclusion: This case suggests that integrative oncology combining systemic anticancer therapy with high-dose vitamin C and Viscum album extracts may enhance tolerance and extend survival in advanced myxofibrosarcoma. Further prospective studies are warranted to corroborate the value of complementary therapy in sarcoma management.
Gigineishvili et al. (Mon,) studied this question.